Today is July 02, 2024. All times in Eastern Daylight Time.
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
06/02/2024 - 10:56 AM
BUSINESS WIRE
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
06/02/2024 - 10:01 AM
BUSINESS WIRE
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
06/02/2024 - 09:30 AM
BUSINESS WIRE
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
06/02/2024 - 09:00 AM
BUSINESS WIRE
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
06/02/2024 - 08:30 AM
BUSINESS WIRE
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
06/02/2024 - 08:30 AM
BUSINESS WIRE
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
06/02/2024 - 08:05 AM
BUSINESS WIRE
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
06/02/2024 - 08:00 AM
BUSINESS WIRE
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
06/02/2024 - 08:00 AM
BUSINESS WIRE
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
06/02/2024 - 08:00 AM
BUSINESS WIRE
1
...
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
« Previous
Next »